Creative Touch Permanent Makeup and Aesthetics

Corticosterone is the dominant glucocorticoid in rodents and a secondary one in humans, produced alongside cortisol by the adrenal cortex and locally activated in skin by 11β-HSD1. It is best understood in the skin context as the hormonal mediator through which animal stress research translates (or doesn’t) to human clinical findings. Its most clearly evidenced skin-specific role is in hair follicle cycling: chronic elevation suppresses hair follicle stem cell activation by preventing dermal papilla cells from secreting the GAS6 protein required to trigger hair regrowth.

Corticosterone is a steroid glucocorticoid produced by the zona fasciculata of the adrenal cortex in response to HPA axis activation. This is the same production pathway and the same stimulus as cortisol, but through a different enzymatic route at the final synthesis step. The critical species distinction that defines this entity’s purpose in the knowledge base: corticosterone is the dominant glucocorticoid in rodents – mice and rats – where cortisol levels are below 1% of corticosterone levels. ^[1] In humans, cortisol is the dominant glucocorticoid and corticosterone is produced in smaller quantities as a secondary steroid. Both are present in human skin, both are locally activated by 11β-HSD1 in keratinocytes and fibroblasts, and both act through the same glucocorticoid receptor. ^[6]

Understanding this species distinction determines whether the extensive body of murine stress and skin research translates directly to human clinical conclusions. When a mouse study reports that chronic stress impairs hair regrowth, suppresses keratinocyte proliferation, or delays barrier recovery through glucocorticoid action, the mediating hormone is corticosterone. The human equivalent of that mechanism is cortisol, acting through the same receptor pathway. The biology is directly translatable in mechanism; the hormone names should not be conflated.

Corticosterone and Human Skin: The Local Production Picture

In humans, corticosterone’s skin relevance is not as a replacement for cortisol but as an additional glucocorticoid signal within the same local activation system. The enzyme 11β-HSD1 in keratinocytes and dermal fibroblasts converts inactive precursors into active glucocorticoids. In humans, this means primarily cortisol activation from cortisone, alongside a smaller but non-negligible corticosterone contribution from 11-dehydrocorticosterone. ^[5] Both contribute to the cumulative intracellular glucocorticoid load that suppresses fibroblast collagen synthesis, impairs keratinocyte differentiation, and inhibits barrier lipid production – the mechanisms described in the Cortisol entity. Corticosterone does not create new skin biology in humans; it adds to the glucocorticoid burden through the same receptor and the same downstream pathways.

What makes the local tissue picture more complex than plasma measurements suggest is that tissue-level corticosteroid concentrations can amplify disproportionately under stress relative to plasma. In stressed mice, local tissue corticosterone concentrations increased 19 to 75-fold compared to a 26-fold increase in plasma – evidence that tissue-specific amplification occurs independently of and beyond systemic levels. ^[7] The human equivalent, mediated through cortisol and 11β-HSD1 upregulation in stressed skin, is established in the Cortisol entity. The corticosterone data from rodents provides mechanistic confirmation that the tissue amplification effect is a real feature of local glucocorticoid biology rather than an artefact.

The Hair Follicle Mechanism: GAS6 and Dermal Papilla Suppression

The most clearly evidenced and mechanistically complete skin-specific role for corticosterone is in hair follicle cycling, and it is worth stating precisely because the mechanism is more specific than “stress hormones impair hair growth.”

Chronic corticosterone elevation in mice produced sustained hair follicle quiescence, i.e. follicles remained in an extended telogen (resting) phase and failed to transition to anagen (active growth). The critical finding was that corticosterone was not acting directly on hair follicle stem cells. Instead, it was acting on the dermal papilla – the cluster of specialised fibroblasts beneath the hair follicle – and suppressing the secretion of GAS6, a signalling molecule produced by dermal papilla cells that is required to activate hair follicle stem cells and initiate anagen. When GAS6 was restored by direct delivery into the skin, hair regrowth resumed in corticosterone-treated mice, confirming the causal pathway. ^[2]

The dermal papilla, as a specialised fibroblast population, is particularly glucocorticoid-sensitive. Suppression of its GAS6 secretion represents a specific mechanism through which the general glucocorticoid fibroblast suppression described in the Cortisol entity manifests in the hair follicle context. In humans, the equivalent mechanism operates through cortisol, but the precise GAS6–dermal papilla pathway established in the corticosterone rodent model is the evidence base for understanding why chronic stress, caloric restriction, and rapid weight loss all produce telogen effluvium through a glucocorticoid-mediated route. ^[3]

The GAS6 Hair Loss Cascade

Corticosterone, Rodent Models, and the Research Translation Problem

A significant proportion of the mechanistic skin research that informs clinical practice was conducted in rodent models. This matters for interpreting that literature carefully:

• Barrier recovery delay studies using tape-stripping and psychological stress protocols in mice are corticosterone-mediated. The translation to human cortisol-mediated barrier delay is well-established and the barrier-recovery delay confirmed in human studies, but the animal and human evidence should be cited distinctly.
• Hair follicle cycle disruption studies, including the GAS6–dermal papilla work above, are corticosterone studies. Translation to human cortisol-mediated hair follicle suppression is mechanistically supported but extrapolated.
• Wound healing delay studies in aged rodents attributing impairment to elevated corticosterone translate to the human 11β-HSD1 cortisol amplification story, not because corticosterone is the human mediator, but because the downstream receptor pathway is the same.